When most investors think of healthcare investment opportunities, their minds go straight to pharmaceutical behemoths like Pfizer, Eli Lilly, and Merck. Yet a younger player—Hims & Hers Health (NYSE: HIMS)—is quietly rewriting the playbook. Since its public debut in January 2021, this